Autopsy report · NCT04752358
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Cause of deathSlow enrollment, also futility
“Study was terminated due to difficulty recruiting subjects and lack of efficacy”
Life of this trial
- Registered 7 months before it started.
- Ran for about 2 years 3 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Adaptimmune
- Sponsor type
- Industry
- Conditions
- Esophageal Cancer; Esophagogastric Junction Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells
- Participants
- 3
- Sites
- 17
- Countries
- Canada, Spain, United States
Trials that died the same way
- Early Versus Late Amniotomy Following EAB Cervical Ripening
“Study was terminated due to difficulties in recruitment” - Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
“The study was terminated due to recruitment challenges” - Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks
“Study terminated due to inadequate recruitment” - Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF
“The study was terminated due to difficulty in recruiting patients.” - Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
“Study terminated early due to difficulties in subject recruitment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.